216311-09-0

Basic information

• Product Name: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol
• Synonyms: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol
• CAS NO: 216311-09-0
• Molecular Weight: 299.388
• Mol File: 216311-09-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol(216311-09-0)
• EPA Substance Registry System: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol(216311-09-0)

Safety Data

• Hazardous Substances Data: 216311-09-0(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1422-53-3 2-bromo-4-fluorotoluene 
• 30897-90-6 (2-methyl-4-fluorophenyl)magnesium bromide 
• 452-63-1 2-Bromo-5-fluorotoluene 

Downstream Products

• 1400928-62-2 1-{3-[4-(4-fluoro-2-methylphenyl)piperidin-1-yl]propanoyl}-N,N-dimethylindoline-(2S)-2-carboxamide monocitrate 
• 1400928-48-4 C₂₆H₃₂FN₃O₂ 
• 216311-10-3 1-benzyl-4-(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydropyridine 

Relevant articles and documents

Discovery of 1-(β-amino substituted-β-alanyl)-N,N- dimethylindoline-2-carboxamides as novel nonpeptide antagonists of nociceptin/orphanin FQ receptor: Efficient design, synthesis, and structure-activity relationship studies

Since the discovery of endogenous nociceptin/orphanin FQ (N/OFQ) peptide and N/OFQ peptide (NOP) receptor [or opioid-receptor-like-1 (ORL1) receptor], the structures, distribution, and pharmacology have been reported in detail. N/OFQ and NOP receptor are

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.